Overall survival calculated from PM manifestation to death.

<p>Overall survival calculated from PM manifestation to death.</p

Disease control rate based on age subgroups.

<p>Disease control rate based on age subgroups.</p

Correlation between change in C (panel A), T (panel B), C+T (panel C) and basal BMI (D) with Clinical Benefit (SD or PR as best response) during everolimus therapy.

<p>Correlation between change in C (panel A), T (panel B), C+T (panel C) and basal BMI (D) with Clinical Benefit (SD or PR as best response) during everolimus therapy.</p

Overall survival based on age subgroups.

<p>Overall survival based on age subgroups.</p

Overall survival for patients who underwent pancreatic local treatment (surgery or radiation therapy) and in those who received TTs only.

<p>Overall survival for patients who underwent pancreatic local treatment (surgery or radiation therapy) and in those who received TTs only.</p

Outcome according to MSKCC prognostic group for patients who received only TTs and for those who received pancreatic local treatment (surgery or local radiation therapy).

<p>Outcome according to MSKCC prognostic group for patients who received only TTs and for those who received pancreatic local treatment (surgery or local radiation therapy).</p

Overall survival in the entire study population according to Memorial Sloan Kettering Cancer Center prognostic risk score.

<p>Overall survival in the entire study population according to Memorial Sloan Kettering Cancer Center prognostic risk score.</p

Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma (<i>N</i> = 398).

<p>Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma (<i>N</i> = 398).</p

Patient characteristics in the control group (n = 330).

<p>Patient characteristics in the control group (n = 330).</p

Overall survival calculated from initiation of first-line TTs for PM patients and the control group.

<p>Overall survival calculated from initiation of first-line TTs for PM patients and the control group.</p